Home>Biopharmaceutical Manufacturing>Managing Aggregates in Your Monoclonal Antibody (mAb) Process

Managing Aggregates in Your Monoclonal Antibody (mAb) Process

Watch Our Webinar!

Product Aggregation in Bioprocessing: Origins, Prevention, and Removal

Register Now

Aggregates in mAb therapeutics pose a risk to patients. Are you considering how best to manage and remove aggregates across your template?

In this 6-part video series, watch our experts discuss which steps in the biomanufacturing process are involved in the formation or removal of aggregates and industry-leading approaches.

Request Information

Upstream

Michael A. Cunningham, Ph.D., Associate Director, Applications Engineering, focuses on how upstream unit operations including clone selection, process optimization such as nutrient optimization and oxygen availability can impact monoclonal antibody aggregation in your process.

Affinity and Ion Exchange Chromatography

Santosh B. Rahane, Ph.D, Senior Research Scientist, addresses the removal of mAb aggregates from monomeric products using protein A affinity, cation exchange (CEX), and anion exchange (AEX) chromatography steps in both bind/elute and flow through modes.

Virus Filtration

David Bohonak, PhD, Senior Applications Engineer, speaks about the effects of protein aggregation on virus filtration. The types of aggregates, considerations for viral clearance studies, and the use of adsorptive prefiltration for aggregate removal are discussed.

Ultrafiltration/Diafiltration (UF/DF)

Emily Peterson, Senior Biomanufacturing Engineer, discusses how careful selection of operation conditions and Tangential Flow Filtration (TFF) system design impacts aggregate formation within the UF/DF process.